Therapeutic effect of topical application of linoleic acid and lincomycin in combination with betamethasone valerate in melasma patients
Lee MH, Kim HJ, Ha DJ, Paik JH, Kim HY
Journal of Korean medical science · 28 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2002-01-01 · J Korean Med Sci · vol. 17 · número 4 · pág. 518
- Editorial
- Korean Academy of Medical Sciences
- Citado
- 39 citas · más que el 66% de estudios similares · 0.3× el promedio de su campo
- Referencias
- 20 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Dermatologic Treatments and Research · melanin and skin pigmentation · Cutaneous Melanoma Detection and Management
- Palabras clave
- melasma, linoleic acid, lincomycin, betamethasone valerate, topical combination therapy, melanogenesis inhibition, Melasma Area and Severity Index, facial hyperpigmentation, anti-melanogenic agents
- MeSH
- humans, melanosis, lincomycin, linoleic acid, anti-inflammatory agents, ointments, drug combinations, glucocorticoids, anti-bacterial agents, administration, topical, double-blind method, molecular structure, adult, middle aged, korea, female, male, betamethasone valerate
5 autores
- Mu‐Hyoung Lee🇰🇷Kyung Hee University
- Hyun Jin Kim🇰🇷Kyung Hee University
- Dong-Ju Ha🇰🇷Kyung Hee University
- Jong Han Paik🇰🇷Kyung Hee University
- Hong Yong Kim🇰🇷Kyung Hee University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Melasma is an acquired symmetric hypermelanosis characterized by irregular light-to gray-brown macules and patches on sun-exposed areas. Many therapeutic agents are available but are unsatisfactory. Recently, it has been demonstrated that lincomycin (LM) and linoleic acid (LA) can inhibit melanogenesis in vitro. Our purpose was to investigate the clinical efficacy of topical application of LM and LA in combination with betamethasone valerate (BV) in melasma patients. Forty-seven Korean female adults with clinically diagnosed melasma were enrolled in a 6-week, double-blind, randomized clinical trial. Patients were treated with one application of the vehicle (group A), 2% LM mixed with 0.05% BV (group B), or 2% LM mixed with 0.05% BV and 2% LA (group C) on the face every night. Determination of efficacy was based on the Melasma Area and Severity Index (MASI) score and objective assessment (no effect, mild, moderate, or excellent) at intervals of 2 weeks until the end of the study at 6 weeks. After 6 weeks, in comparison with the pre-treatment MASI score, the average MASI score of group C decreased to 68.9%, compared with 98% in group A (p<0.05) and 85.4% in group B. There was no statistically significant difference between group A and group B. Seven patients (43.7%) in group C revealed more than moderate improvement in objective assessment, compared with none in group A and two patients (12.5%) in group B. There were no significant side effects. Topical application of linoleic acid is considered to be effective in the treatment of melasma patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.